Interestingly, oxepinamides D-G and H−K (12–15, 32–35) all selectively showed transactivation effects on LXRα, which implied their potential use as novel LXR agonists in the treatment of atherosclerosis, diabetes, and Alzheimer’s disease. The gene discussed is NR1H3; the disease is atherosclerosis.